Refractory status epilepticus.
dc.contributor.author | Murthy, J M K | en_US |
dc.date.accessioned | 2006-12-23 | en_US |
dc.date.accessioned | 2009-06-03T12:14:28Z | |
dc.date.available | 2006-12-23 | en_US |
dc.date.available | 2009-06-03T12:14:28Z | |
dc.date.issued | 2006-12-23 | en_US |
dc.description | 73 references. | en_US |
dc.description.abstract | Refractory status epilepticus (RSE) is a common problem in intensive care units and emergency departments. The important risk factor predisposing patients with SE to RSE is delay in receiving treatment. Self-sustaining SE is associated with progressive, time-dependent development of pharmacoresistance. Early termination of convulsive SE by aggressive treatment is the best way to prevent RSE. RSE once develop, requires more aggressive treatment as it is associated with higher mortality and morbidity. To date, no randomized controlled trials have been done for RSE. The most experience exists with coma inducing agents like pentobarbital, midazolam and propofol. New evidence suggests for the possible role of newer AEDs. | en_US |
dc.description.affiliation | Department of Neurology, The Institute of Neurological Sciences, CARE Hospital, Nampally, Hyderabad - 500 001, India. jmkmurthy@satyam.net.in | en_US |
dc.identifier.citation | Murthy JM. Refractory status epilepticus. Neurology India. 2006 Dec; 54(4): 354-8 | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/121422 | |
dc.language.iso | eng | en_US |
dc.source.uri | https://neurologyindia.com | en_US |
dc.subject.mesh | Anticonvulsants --therapeutic use | en_US |
dc.subject.mesh | Electroencephalography | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Risk Factors | en_US |
dc.subject.mesh | Status Epilepticus --diagnosis | en_US |
dc.title | Refractory status epilepticus. | en_US |
dc.type | Journal Article | en_US |
dc.type | Review | en_US |
Files
License bundle
1 - 1 of 1